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Transcriptional regulationThe ORF61 and ORF60 genes of Kaposi's sarcoma-associated herpesvirus (KSHV) encode the ribonucleotide
reductase large and small subunits, respectively. Here we show that ORF50 protein, a latent-lytic switch
transactivator, activates the transcription of these two early-lytic genes through different mechanisms.
Activation of the ORF61 promoter by ORF50 protein is dependent on an intact RBP-Jκ-binding site within the
identiﬁed responsive element and the expression of RBP-Jκ protein in cells. The critical element in the ORF60
promoter in response to ORF50 was mapped to a 40-bp region. Binding of YY1, Sp1/Sp3 or unknown
proteins to this element may contribute to repression or activation of the ORF60 promoter. Although ORF50
protein does not directly bind to the ORF61 and ORF60 promoters in vitro, we show the association of ORF50
protein with these two promoters in vivo. Our results provide further insights into the regulatory network of
the viral lytic genes in KSHV reactivation.
© 2009 Elsevier Inc. All rights reserved.Introduction
Kaposi's sarcoma-associated herpesvirus (KSHV), also known as
human herpesvirus 8, is a gammaherpesvirus associated with at least
three malignancies: Kaposi's sarcoma, primary effusion lymphoma
and multicentric Castleman's disease (Boshoff et al., 1995; Cesarman
et al., 1995; Chang et al., 1994; Soulier et al., 1995). An important step
for viral propagation and pathogenesis is the switch from latency to
lytic replication (Martin et al., 1999; Miller et al., 1997). Upon
reactivation from latency, the viral lytic genes are expressed in a
temporally ordered fashion, ultimately leading to the production of
infectious virions (Gradoville et al., 2000). The lytic genes can be
classiﬁed into three categories: immediate-early, early and late genes
(Miller et al., 1997; Sun et al., 1999). The immediate-early genes
usually encode regulatory proteins that modulate expression of viral
and host genes, which facilitate later stages of lytic replication (Zhu et
al., 1999). Following expression of the immediate-early genes, the
early genes that encode essential components for viral lytic DNA
synthesis are induced. In addition to the replication proteins, thety, Chiayi, Taiwan. Fax: +886 5
ng).
ll rights reserved.KSHV early gene products also include transcriptional modulators,
signal transducers, cytokines and immunomodulatory proteins
(Dourmishev et al., 2003). After lytic DNA synthesis, viral capsid
proteins or structural glycoproteins are expressed at late stages.
Expression of these lytic genes in different categories must be tightly
controlled during the entire lytic cycle.
The ORF50 protein encoded by open reading frame 50 (ORF50) of
the viral genome is an immediate-early protein, which is a key
regulator for the switch of the virus from latency to lytic replication
(Lukac et al., 1999, 1998; Sun et al., 1998). The ORF50 protein is a
potent transcriptional activator with an N-terminal basic DNA-
binding domain and a C-terminal acidic activation domain (Chang
and Miller, 2004; Chang et al., 2002; Wang et al., 2001). Ectopic
expression of ORF50 protein in latently KSHV-infected cells triggers
the viral lytic cascade to completion (Lukac et al., 1998; Sun et al.,
1998). All of the viral early genes with the similar expression kinetics
must be under the control of ORF50 protein during lytic cycle.
However, not all tested promoters of the early lytic genes are
activated through the direct binding of ORF50 to the promoters
(Chang et al., 2005; Liang et al., 2002). Thus, ORF50 proteinmay utilize
different strategies to cooperate with other viral or cellular proteins to
regulate the diverse early gene expression.
A subset of the early gene promoters activated by ORF50 have been
identiﬁed, including polyadenylated nuclear (PAN) RNA, K12, ORF57,
312 S.-S. Wang et al. / Virology 397 (2010) 311–321K8, K9 (vIRF), ORF21, K3, K5, K6 (vMIP-1), ORF6, K14 (vOX-2), ORF74
(vGPCR), K2 (vIL-6), ORF59 and ORF50 itself (Chang et al., 2002, 2005;
Chen et al., 2000; Deng et al., 2002, 2000; Haque et al., 2000; Jeong et
al., 2001; Liu et al., 2008; Lukac et al., 2001, 1999; Song et al., 2001;
Wang and Yuan, 2007; Zhang et al., 1998). Among the known targets,
PAN and K12 are activated through a direct binding of ORF50 to their
promoters (Chang et al., 2002). A highly conservative core element,
5′-AAATGGGTGGCTAACC, for ORF50 binding is required for the
activation. Conversely, ORF50 may activate transcription through
indirect access to DNA via protein-protein interaction (Chang et al.,
2005; Liang et al., 2002). The best-characterized protein involving in
the ORF50-mediated transactivation is RBP-Jκ (CSL/CBF1), a primary
effector of the Notch pathway (Lai, 2002). The ORF50 protein interacts
with RBP-Jκ in vitro and in vivo (Liang et al., 2002). Binding of the RBP-
Jκ protein to the target promoters is critical for recruiting ORF50
protein to activate the transcription. Several promoters of viral genes,
including the ORF57, ORF6, vMIP-1, K14/ORF74, ORF50, K3, K5, K8
and ORF59, have been grouped into this subclass (Chang et al., 2005;
Liang et al., 2002; Liang and Ganem, 2003, 2004; Liu et al., 2008;Wang
and Yuan, 2007). In these promoters, a conserved or related RBP-Jκ
binding site, 5′-GTGGGAA, is found within the identiﬁed ORF50
response elements (ORF50 REs).
Despite extensive studies in the regulation of the early lytic genes,
regulation of numerous viral lytic genes still remains elusive. As other
herpesviruses, KSHV encodes the homolog of ribonucleotide reductase
(RNR) that catalyzes the conversion of ribonucleoside diphosphates to
the corresponding deoxyribonucleotides to provide a balanced supply
of precursors for DNA synthesis (Jordan andReichard, 1998). TheKSHV
RNR is composed of two subunits: the large subunit encoded by open
reading frame 61 (ORF61) and the small subunit by open reading frame
60 (ORF60) (Russo et al., 1996). Since the viral RNRpotentially involves
the control of the cellular concentration of deoxyribonucleotides,
expression of the ORF61 and ORF60 genes may be important for lytic
DNA replication. In this report, we study the transcriptional regulation
of these two lytic genes in response to ORF50 protein in different cell
lines. The detailed regulatory networks mediated by ORF50 protein in
activating the ORF61 and ORF60 promoters are proposed.
Results
Expression kinetics and transcriptional mapping of the ORF61 and
ORF60 genes
To analyze the expression kinetics of the ORF61 and ORF60 genes
during lytic cycle, total RNAs prepared from HH-B2 cells treated with
sodium butyrate were subjected to Northern analysis. Phosphonoa-
cetic acid (PAA), an inhibitor of lytic replication, was also added in
butyrate-treated cells to differentiate the early from late transcripts.
Northern analysis revealed that two transcripts that were 6.0 and
3.5 kb long were detected using an ORF60-speciﬁc probe and were
expressed at maximal levels at 12 to 24 h after lytic induction (Fig.
1B). Furthermore, PAA did not seem to affect the transcription. The
6.0-kb transcript may contain ORF61, ORF60, ORF59 and ORF58; the
3.5-kb transcript may contain ORF60, ORF59 and ORF58 (Majerciak et
al., 2006). To determine the location of the ORF61 and ORF60
promoters, wemapped the 5′ transcriptional start site of each gene by
RACE (rapid ampliﬁcation of the cDNA ends). The start site of the
ORF61 transcript was mapped at nucleotide (nt) 100329 of the KSHV
genome (Russo et al., 1996) (Figs. 1A and C). Whereas two
transcriptional start sites, nt 97843 (major) and nt 97845 (minor),
were mapped to the ORF60 transcript (Figs. 1A and C). Upstream of
the identiﬁed transcriptional start sites, a consensus TATA box (5′-
TATATAAA) and a TATA-like box (5′-TAAAAA) were found in the
ORF61 promoter (ORF61p) and the ORF60 promoter (ORF60p),
respectively (Fig. 1D). The corresponding 3′ polyadenylation cleavage
sites of the ORF61 and ORF60 transcripts were predicted based on thelength of the transcripts in our Northern analysis and the 3′
transcriptional mapping of the ORF58 and ORF59 genes reported
previously by Majerciak et al. (2006). There were two adjacent 5′-
AAUAAA signals at the 3′ end of the transcripts (Fig. 1A).
Distinct mechanisms operated by ORF50 protein in activating the ORF61
and ORF60 promoters
To determine whether ORF50 protein directly regulated the ORF61
and ORF60 promoters, regions of about 1 kb in the ORF61 and ORF60
promoters were cloned into pGL3-Basic, a luciferase reporter plasmid.
Two ORF50-responsive promoters, PANp and ORF57p, were also
included in the experiment (Fig. 2). The luciferase activity of these
reporters in HKB5/B5, 293T and HH-B2 cells was monitored with a
luminometer. Both HKB5/B5 and 293T are KSHV-negative cell lines,
whereas HH-B2 is a latently KSHV-infected cell line. As illustrated in
Fig. 2, the ORF50 protein strongly activated the PANp, ORF57p,
ORF61p and ORF60p, 81- to 1156-fold in HH-B2 cells. In HKB5/B5 and
293T cells, the PANp, ORF57p and ORF61p were still substantially
activated by ORF50 protein. However, ORF50 protein activated the
ORF60p only at background levels in HKB5/B5 and 293 T cells (Fig. 2).
These results indicated that ORF50 protein alone sufﬁciently activates
the ORF61p in different cell lines. In contrast, activation of the ORF60p
by ORF50 protein may require other viral or cellular proteins, which
are not adequately expressed in HKB5/B5 and 293T cells.
Deﬁning the ORF50 response element in the ORF61 promoter
Since the ORF50 protein activated the ORF61p, we determined the
ORF50 response element (ORF50 RE) of the ORF61 promoter.
Deletions in the ORF61p were constructed to examine their ORF50
responsiveness in HKB5/B5, 293T and HH-B2 cells (Fig. 3A). Although
the ORF50 responsiveness of the ORF61 promoter in different cell lines
varied, the ORF50 responsive region in the promoter was consistently
mapped to the region between −344 and −123 (Fig. 3A). To deﬁne
the minimal ORF50 RE in the ORF61p, the region encompassing−344
to −123 or its deleted elements (Fig. 3B) was fused to pE4luc, a
luciferase reporter plasmid containing a minimal adenovirus E4
promoter. When the reporter containing the region from −344 to
−123 was cotransfected with an ORF50-expressing plasmid in HKB5/
B5 and 293T cells, a 16- and 46-fold enhancement of luciferase activity
was detected in HKB5/B5 and 293T cells (Fig. 3B). Based on the results
from Fig. 3B, the minimal ORF50 RE of the ORF61p was mapped to a
40-bp element from −194 to −155 (Fig. 3B; RE-6). Further deleting
the 3′ region of the RE-6 element to −175 completely abolished the
response to ORF50 protein in both cell lines, whereas 5′ deletion of the
RE-6 element to−187 had a decreased ORF50 responsiveness by 22%
in HKB5/B5 cells and 19% in 293T cells (Fig. 3B).
Binding of RBP-Jκ to the ORF50 RE in the ORF61 promoter
Sequence analysis of ORF61p(−194/−155) revealed that this
region contained a putativeRBP-Jκ recognition sequence, 5′-GTGTGAA,
between −165 and −159 (Fig. 4A). To determine whether the
putative RBP-Jκ site in ORF61p(−194/−155) was important to the
transactivation by ORF50, point mutations were introduced into the
element (Fig. 4A). Mutation at the putative RBP-Jκ site reduced the
ORF50 responsiveness to background levels in HKB5/B5 and 293T cells
(Figs. 4B andC; F-mt).Mutationsﬂanking theRBP-Jκ site of theORF61p
(−194/−155) element also resulted in reduction of their ORF50
responsiveness by 26% to 60% in HKB5/B5 cells and 46% to 64% in 293T
cells (Fig. 4B and C), suggesting that the region ﬂanking the RBP-Jκ
recognition site is also critical for the full ORF50 responsiveness.
To determine the binding of ORF50 or RBP-Jκ protein to the
ORF61p(−194/−155) element, extracts from HKB5/B5 cells trans-
fected with pCMV, pCMV-FLAG-ORF50, pCMV-FLAG-ORF50(1–390)
Fig. 1. Expression and determination of the transcription start sites of the ORF61 and ORF60 genes. (A) Schematic diagram of the ORF61 and ORF60 transcripts. Numbers in the
diagram represent the nucleotide positions of the KSHV genome (Russo et al., 1996). Arrows represent transcriptional start and cleavage sites. (B) Northern blot analysis of the
ORF61 and ORF60 transcripts. Total RNAs were prepared from HH-B2 cells that were treated with 3 mM sodium butyrate (SB) for 12, 24, 36 and 48 h in the presence or absence of
200 μg phosphonoacetic acid (PAA) per ml. The DNA fragment from nt 97527 to 97843 was used as a probe for Northern analysis. Hybridization with H1 RNA of RNase P served as a
loading control. (C) Mapping of the transcriptional start sites of the ORF61 and ORF60 transcripts by RACE. Total RNAs from HH-B2 cells treated with sodium butyrate for 30 h were
subjected to RACE analysis as described in Materials and methods. The 5′ regions of the ORF61 and ORF60 transcripts ampliﬁed in RACE experiments were shown. (D) Sequence of
the basal promoter of the ORF61 and ORF60 genes. Arrows and the open boxes represent the transcriptional start sites and the TATA boxes, respectively. The transcriptional start site
of the ORF61 gene was mapped to nt 100329, whereas the transcriptional start site of the ORF60 gene was mapped to nt 97843 (major) or nt 97845 (minor).
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(1–390) protein contains only the DNA-binding domain from aa 1 to
390 of ORF50 protein. The study found that FLAG-RBP-Jκ protein, but
not the full-length ORF50 and ORF50(1–390), bound to the ORF61p
(−194/−155) probe (Fig. 4D). The DNA/RBP-Jκ complex formed in
EMSA was also conﬁrmed by supershifting the complex with an anti-
FLAG antibody (Fig. 4D). As shown in Fig. 4E, formation of the DNA/
RBP-Jκ complex was blocked with excessive competitors RE-6, M-mt
and R-mt, but not the F-mt cold competitor. The data suggested that
the RBP-Jκ protein binds to the 5′-GTGTGAA sequence. Furthermore,
when the RBP-Jκ recognition site, 5′-GTGTGAA, in the ORF61p(−194/
−155) element was converted to a conserved RBP-Jκ site, GTGGGAA
[Fig. 4A; RBP(+)], the single point mutation present in the ORF61p
(−194/−155) element exhibited 1.6- and 1.5-fold greater ORF50
responsiveness than the wild-type RE-6 element in HKB5/B5 and
293T cells [Figs. 4B and C; RBP(+)].
Involvement of the RBP-Jκ protein in activating the ORF61 promoter
Next, we examined the role of RBP-Jκ protein in activation of the
ORF61p by ORF50 protein. The embryonic ﬁbroblast cell line OT11(kindly provided by Dr. T. Honjo, Kyoto University, Kyoto, Japan)
derived from the RBP-Jκ knockout mouse was used to analyze the
ORF50 transactivation. The parental wild-type mouse cell line OT13
was also used as a control for analyzing the ORF50 transactivation. The
ORF61p and PANp revealed a 61- and 121-fold enhancement of
luciferase activity in OT13 cells (Fig. 4F). However, little response of
the ORF61p to ORF50 protein was detected in OT11 cells (Fig. 4G).
Notably, the PANp still conferred strong ORF50 responsiveness (48-
fold) in OT11 cells. When the plasmid expressing RBP-Jκ was
introduced into OT11 cells, activation of the ORF61p by ORF50 was
restored (Fig. 4G), indicating that ORF50 activates the ORF61
promoter though the RBP-Jκ protein.
Deﬁning the ORF50 regulatory element in the ORF60 promoter
Although the ORF60p was not a direct target of ORF50 protein,
activation of the ORF60p remained under the control of ORF50 protein
in the KSHV-infected cells (Fig. 2). To investigate the regulatory
network that inﬂuences the transcription from this promoter, we
determined the location of the ORF50 regulatory element in the
ORF60p in HH-B2 cells. A series of 5′ deletions of the ORF60p were
Fig. 2. Transcriptional activation of viral promoters by the ORF50 protein in different cell lines. The promoter regions from the PAN and ORF57, ORF61, ORF60 genes were cloned into
pGL3-Basic. The reporter plasmids were individually cotransfected with pCMV or pCMV-FLAG-ORF50 into HKB5/B5, 293T and HH-B2 cells. At 48-h post-transfection in HKB5/B5 and
293 cells or at 24-h post-transfection in HH-B2 cells, the luciferase activity of the reporters was measured. The fold activation was calculated as the luciferase activity in the presence
of the ORF50-expressing plasmid divided by luciferase activity in the presence of control vector pCMV. The means and standard deviations from at least three independent
transfections are shown.
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Transient reporter assay revealed that 5′ deletion to −70 relative to
the transcription start site retained nearly full responsiveness to the
ORF50 protein in HH-B2 cells. However, the response was lost when
the deletion was extended to −31 (Fig. 5A). To further conﬁrm the
importance of the regulatory element responding to the ORF50
protein in the ORF60p, the region from−71 to−−32 of the ORF60p
was subcloned into pE4luc. This 40-bp sequence in pE4luc conferred
37-fold activation in response to ORF50 in HH-B2 cells (Fig. 5B). Point
mutations were also generated in this 40-bp regulatory element.
Mutation in the middle region of the regulatory element led to
background activation by ORF50 protein, whereas mutations at the
ﬂanking region also resulted in reduction of the ORF50 transactivation
(Fig. 5B).
Binding of YY1, Sp1/Sp3 and unknown proteins to the ORF60 promoter
To determine the binding capacity of cellular and viral proteins to
the ORF60p(−71/−32) element, extracts fromHH-B2 cells that were
treated or untreated with sodium butyrate were used in EMSA
experiments. Two major DNA/protein complexes, designated A1 and
A3, were detected in EMSA using the untreated cell extract, whereas
an extra DNA/protein complex A2 was present if the butyrate-treated
extract was used (Fig. 6A). Notably, formation of the complex A1 and
A3 in EMSA using the butyrate-treated cell extract was less abundant
than that using the untreated cell extract (Fig. 6A). By using excessive
cold competitors in EMSA, we found that the protein components of
the complex A1 and A3 speciﬁcally bound to the middle region in the
regulatory element (Fig. 6A). By contrast, the protein component of
the complex A2 displayed nonspeciﬁc-binding feature to the
regulatory element. Sequence analysis revealed that a consensus
YY1 binding site, 5′-CCATNTT (Hyde-DeRuyscher et al., 1995), and an
Sp1 (or Sp3) binding site, 5′-GGGGCGTGG (Li et al., 2004), were
present in the middle region of the regulatory element (Fig. 5B). To
determine whether ORF50 or these cellular proteins bound to the
ORF60p(−71/−32) element, antibodies speciﬁc to ORF50, YY1, Sp1
and Sp3 were used to supershift the complexes formed in EMSA.
Addition of the anti-ORF50 antibody did not affect the formation of
the DNA/protein complexes in EMSA (Fig. 6B). However, either
monoclonal or polyclonal YY1 antibody was sufﬁcient to remove thecomplex A3, suggesting that YY1 protein was an important compo-
nent of the complex A3. After removal of the YY1 complex, we found a
faint DNA/protein complex (A3′), which co-migrated with the
complex A3, detected only in EMSA using the extract from butyrate-
treated HH-B2 cells (Fig. 6B). When the Sp1 and Sp3 antibodies were
used in the reaction, the complex A1 formed in EMSA was partly
reduced (Fig. 6B). To further conﬁrm whether ORF50, YY1 or Sp
proteins bound to the regulatory element of the ORF60 promoter, cell
extracts containing the overexpressed FLAG-ORF50, FLAG-ORF50(1–
390), FLAG-YY1 or FLAG-Sp1(300–785) were used in EMSA. The
FLAG-Sp1(300–785) contains the DNA-binding domain of Sp1 (Li et
al., 2004). As shown in Fig. 6C, YY1 and Sp1(300–785), but not full-
length ORF50 and ORF50(1–390), bound to the ORF60p(−71/−32)
element. These results imply that different cellular (or viral) proteins
bound to the ORF60p under latent or lytic conditionmay contribute to
repress or activate the gene expression.
Down-regulation of YY1, Sp1 and Sp3 during KSHV lytic cycle
The reduced binding of YY1 and Sp1/Sp3 proteins to the ORF60p
(−71/−32) element in lytic condition shown in Fig. 6 prompted us to
determine whether the expression of YY1, Sp1 and Sp3 proteins was
affected during KSHV lytic replication. Protein extracts from HH-B2
cells treated with sodium butyrate for 24 and 48 h were prepared and
subjected to Western blot analysis. As expected, two viral lytic
proteins, ORF50 and K8, were induced at 24 h after sodium butyrate
treatment (Fig. 7A). However, the expression of YY1, Sp1 and Sp3 was
reduced in a time-dependent manner (Fig. 7A). Furthermore, the
KSHV lytic cycle was also induced in a cell line HH-B2(Tet-On-F-
ORF50) in which expression of exogenous ORF50 gene is regulated
under the control of the doxycycline-induced promoter. Similar to
that in the parental HH-B2 cells after butyrate treatment, expression
of YY1, Sp1 and Sp3 proteins in HH-B2(Tet-On-F-ORF50) was reduced
in a time-dependent manner after viral lytic induction with
doxycycline (Fig. 7B).
Repressive effect of YY1 on the ORF60p activation
Due to the presence of the YY1 binding site in the ORF60p(−71/
−32), we examined the effects of the overexpressed YY1 on the
Fig. 3. Deﬁning the ORF50 response element (ORF50 RE) of the ORF61 promoter. (A) Responsiveness of 5′ deletion mutants of the ORF61 promoter to the ORF50 protein in HKB5/B5,
293T and HH-B2 cells. Activation of the 5′ deleted ORF61 promoter by ORF50 protein in cells was determined by luciferase assay and activation fold was calculated as described
above. (B) Fine mapping of the ORF50 RE within the ORF61 promoter. The ORF61p elements shown in the diagram were cloned into pE4luc, a luciferase reporter plasmid containing
the adenovirus minimal E4 promoter. The reporter activation of each construct in response to ORF50 protein was determined in HKB5/B5 and 293T cells.
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reporter plasmids that contain the E2F-binding site and the ORF61p
(−194/−155) element in pE4luc were also included in the
experiment. Increasing amounts of the YY1-expressing plasmid
were cotransfected with the reporters and the ORF50-expressing
plasmid into HH-B2 cells. At 24-h post-transfection in HH-B2 cells, the
luciferase activity of the reporters was measured. The pE2F/E4luc
exhibited a background level activation by ORF50 and was weakly
repressed by YY1 (Fig. 8A). However, the increasing amounts of YY1
signiﬁcantly repressed the activation of the ORF60p(−71/−32)/
E4luc by ORF50 in a dose-dependent manner (Figs. 8B and D). Littlerepressive effect was detected for the reporter ORF61p(−194/−155)/
E4luc in the presence of the overexpressed YY1 (Figs. 8C and D).
Binding of ORF50 protein to the ORF61 and ORF60 promoters in vivo
Association of ORF50 and RBP-Jκwith the viral lytic promoters was
determined in HH-B2 and in HH-B2(Tet-On-F-ORF50) cells by
chromatin immunoprecipitation (ChIP). Chromatin extracts of HH-
B2 treated with sodium butyrate for 24 h or HH-B2(Tet-On-F-ORF50)
treated with doxycycline for 24 h were immunoprecipitated with
antibodies to ORF50, actin and RBP-Jκ. The association between
Fig. 4. Involvement of RBP-Jκ protein in the activation of the ORF61 promoter by ORF50. (A) DNA sequence of the wild-type and mutant ORF50 REs of the ORF61p. A putative RBP-Jκ
binding site and the mutated sequences in the ORF50 RE of the ORF61p were shown in the diagram. (B and C) The luciferase activities of the indicated reporters in response to ORF50
were examined in HKB5/B5 and in 293T. (D) Binding of the RBP-Jκ protein to the ORF50 RE of the ORF61 promoter. Extracts of HKB5/B5 cells transfected with pCMV, pCMV-FLAG-
ORF50, pCMV-FLAG-ORF50(1–390) or pCMV-FLAG-RBPJκ were used in EMSA. The annealed double-stranded oligonucleotide was labeled with biotin-11-UTP using terminal
deoxynucleotidyl transferase. Antibody to the FLAG tagwas used for supershift tests. (E) Competition assay in EMSA. The indicated cold competitors used in EMSAwere in 25 and 50-
fold molar excesses over the probe. (F) The reporter plasmid containing the entire ORF61p (−1069 to +130) or PANp (−1875 to +34) was cotransfected with pCMV or pCMV-
FLAG-ORF50 into OT13 cells. The ORF50 responsiveness of each promoter was determined by luciferase assay at 48-h post-transfection. Plasmid pGL3-Basic (pGL3-B) represents a
control reporter. (G) The indicated effector plasmids, including pCMV-FLAG-RBP-Jκ and pCMV-FLAG-ORF50, were cotransfected with the reporters in OT11 cells. After 48-h post-
transfection, activation of the reporters by the effectors was determined.
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promoter regions of PAN, ORF57, ORF61, ORF60, ORF62 and LANA as
well as for the coding region of ORF65 (ORF65c). Under our ChIP
conditions, the ORF50 protein expressed in either HH-B2 or HH-B2
(Tet-On-F-ORF50) was consistently associated with the PAN, ORF57,
ORF61 and ORF60 promoters, but not with the ORF62 and LANA
promoters, and the ORF65 coding region (Fig. 9). On the other hand, a
weak but speciﬁc signal for the ORF57p and ORF61p was detected
from RBP-Jκ-immunoprecipitated chromatin (Fig. 9).
Discussion
The KSHV ORF50 protein is a multifunctional replication and
transcription activator that plays a central role in the switch from viral
latency to the lytic cycle (Sun et al., 1998;Wang et al., 2004). Although
several distinct transactivation mechanisms operated by ORF50protein have been elucidated, many early-lytic genes controlled by
ORF50 protein still remain to be classiﬁed and characterized. Here, we
study the transcriptional activation of the ORF61 and ORF60 genes by
ORF50 protein. Although the ORF61 and ORF60 genes have similar
expression kinetics and related functions in the lytic cycle, we found
that ORF50 protein activates these two adjacent genes through
different mechanisms. The most striking difference is that ORF50
protein is unable to activate the ORF60p in KSHV-negative cells
(Fig. 2). Furthermore, we have identiﬁed several speciﬁc cellular
proteins involved in the regulation of the ORF61p and the ORF60p
(Figs. 4, 6 and 8). The functional association between ORF50 and these
diverse cellular proteins emphasizes the versatile actions of the ORF50
protein in lytic replication.
The KSHV ORF61 gene encodes the ribonucleotide reductase large
subunit (Russo et al., 1996). Based on our Northern analysis (Fig. 1B)
and the transcriptional mapping reported by Majerciak et al. (2006),
Fig. 5.Mapping the ORF50 regulatory element of the ORF60 promoter. (A) Responses of
the deletion constructs of the ORF60 promoter to ORF50 in HKB5/B5 and HH-B2 cells.
Schematic diagram of the ORF60 promoter and the size of the ORF60 promoter in each
construct were indicated. (B) The regulatory element from−71 to−32 and itsmutants
in pE4luc were analyzed for their ORF50 responsiveness in HH-B2 cells. Two
overlapping binding sites for YY1 and Sp1/Sp3 were shown in the ORF60p(−71/
−32) element.
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open reading frames 61, 60, 59 and 58 (Fig. 1A). The transcriptional
start site of the polycistronic transcript has beenmapped to nucleotide
position 100329 of KSHV genome (Figs. 1A and C). The ORF61
promoter contains a consensus TATA box, 5′-TATATAAA (Fig. 1D).
Either in KSHV-positive cells or in KSHV-negative cells, ORF50 protein
sufﬁciently activates the ORF61p (Fig. 2). In transient reporter assays,
the ORF50 RE of the ORF61p was found in the region between−194
and−155 (Fig. 3), which contains an RBP-Jκ-like recognition site and
two A/T-trinucleotidemotifs (Fig. 4A). A tandem array of phased A/T-
trinucleotide repeats has previously been suggested to mediate the
binding by ORF50 and confer the ORF50 responsiveness (Liao et al.,2003). However, we did not detect the direct interaction between
ORF50 protein and the ORF61p(−194/−155) element in vitro
(Fig. 4D). At least four ﬁndings in our experiments support that
activation of the ORF61p by ORF50 protein is mediated through RBP-
Jκ. First, RBP-Jκ protein speciﬁcally binds to the putative RBP-Jκ site in
the ORF61p(−194/−155) element in EMSA experiments (Figs. 4D
and E). Secondly, mutation at the RBP-Jκ site of the ORF61p(−194/
−155) element substantially reduces its ORF50 responsiveness
(Figs. 4B and C). Thus, binding of RBP-Jκ protein to this recognition
site appears to be critical to mediate the ORF50 responsiveness.
Thirdly, in RBP-Jκ (−/−) cells, ORF50 protein does not activate the
ORF61p unless RBP-Jκ is supplied in trans (Fig. 4G). Lastly, the
association of RBP-Jκ and ORF50 with the ORF61 promoter in the
context of viral genome is detectable by chromatin immunoprecip-
itation (Fig. 9). Therefore, we conclude that RBP-Jκ is required for
ORF50 to activate the ORF61 promoter. In addition to the RBP-Jκ
binding site, we notice that sequence ﬂanking the RBP-Jκ site is also
essential for a maximal response to ORF50.
The KSHV ORF60 gene encodes the ribonucleotide reductase small
subunit (Russo et al., 1996). The ORF60 transcription starts at two
positions, nt 97843 and 97845with a TATA-like sequence, 5′-TAAAAA,
present upstream of the start sites (Figs. 1C and D). The ORF60
promoter cannot be activated by ORF50 protein in KSHV-negative
cells (Fig. 2). We have mapped the ORF50 regulatory element of the
ORF60 promoter in HH-B2 cells. The ORF50 regulatory element is
located between −71 and −32, which contains two overlapping
binding sites for YY1 and Sp1/Sp3. The YY1, Sp1 and Sp3 proteins are
ubiquitously expressed transcriptional factors. YY1 recognizes a
conserved 5′-CGCCATNTT and function as either a negative or positive
regulator depending upon the promoter context it binds (He and
Margolis, 2002; Hyde-DeRuyscher et al., 1995; Shi et al., 1997). Sp1
and Sp3 are structure-related zinc ﬁnger proteins, but may have
strikingly different functions in cells (Chu and Ferro, 2005; Li et al.,
2004). Both Sp proteins bind and act through GC boxes to regulate
gene expression of multiple target genes (Chu and Ferro, 2005; Li et
al., 2004). The YY1 and Sp1/Sp3 proteins predominantly bound to the
ORF60 promoter in EMSA (Fig. 6). Under the lytic condition, formation
of the YY1/DNA, Sp1/DNA or Sp3/DNA complexes seems to be
reduced (Figs. 6A and B). The down-regulation of YY1, Sp1 and Sp3 at
late time points of the viral reactivationmay be due to the host shutoff
or other regulatory mechanisms. The authentic roles of these cellular
proteins binding to the ORF60 promoter in latently or lytically
infected cells still need to be further addressed. As shown in Fig. 7,
expression of YY1 in cells was reduced in a time-dependent fashion
during the lytic cycle. Furthermore, overexpressing YY1 preferentially
inhibited the activation of the ORF60p, but not the ORF61p (Fig. 8).
These results suggest that YY1 is a repressor for the transcription of
certain lytic genes, such as the ORF60 gene, during lytic replication. In
addition to the repressive effect by YY1, other viral or cellular proteins
directly or indirectly binding to the ORF60 promoter may be required
for the activation of the ORF60 promoter. Two candidate complexes,
A2 and A3′, detected in EMSA (Fig. 6B) may be important for
recruiting ORF50 protein to the ORF60p and then contributing to the
ORF50-mediated transactivation.
Due to the fact that ORF50 protein cannot activate the ORF60p in
KSHV-negative cells, viral proteins besides ORF50 protein may be
required for the activation of the ORF60p during lytic cycle. These
speciﬁc viral proteins could be latent or lytic proteins or both.We have
investigated two lytic transcriptional modulators, ORF57 and K8, in
cooperating with ORF50 protein to activate the ORF60 promoter. The
ORF57 protein is a homolog of the Epstein–Barr virus (EBV) BMLF1
gene product, which acts as a post-transcriptional modulator (Gupta
et al., 2000; Majerciak et al., 2007, 2008). The K8 protein, a homolog
of EBV ZEBRA, often cooperates with ORF50 protein to regulate gene
expression (Izumiya et al., 2003; Lin et al., 1999). However, neither
does the individual protein nor different combinations of ORF57, K8
Fig. 6. Binding of YY1, Sp1/Sp3 and unknown proteins to the regulatory element of the ORF60 promoter. (A) EMSA of the ORF60p(−71 to −32) element. The double-stranded
ORF60p element (−71 to−32) labeled with biotin-11-UTP using terminal deoxynucleotidyl transferase was served as a probe in EMSA. Protein extracts of HH-B2 cells untreated or
treated with sodium butyrate (SB) for 30 h were used in EMSA. The protein/DNA complexes formed in EMSA were indicated. Cold competitors as shown in Fig. 5B were used in 25
and 50-fold molar excesses over the probe. (B) Antibodies to ORF50, YY1, Sp1 and Sp3 were used for supershift analysis in EMSA. Both monoclonal (mono) and polyclonal (poly)
antibodies to YY1 were included in the experiment. Asterisk indicates the protein/DNA complex A3′ that co-migrates with the complex A3. (C) Extracts of HKB5/B5 cells transfected
with pCMV, pCMV-FLAG-ORF50, pCMV-FLAG-ORF50(1–390), pCMV-FLAG-YY1 and pCMV-FLAG-Sp1(300–785) were prepared for EMSA (left panel). Antibody to FLAG was used for
supershift analysis (left panel) and Western analysis (right panel).
318 S.-S. Wang et al. / Virology 397 (2010) 311–321and ORF50 signiﬁcantly activate the ORF60p in HKB5/B5 and 293T
cells (data not shown).
In conclusion, we provide here evidence that ORF50 protein
regulates the ORF61p and ORF60p via distinct cellular transcription
factors. Understanding the diverse regulatory mechanisms operated
by ORF50 protein has enhanced our knowledge about the versatile
actions of the ORF50 protein.Materials and methods
Cell cultures and transfections
293T is derived from human embryonic kidney cells transformed
with the E1 region of adenovirus and the simian virus 40 T antigen.
The 293T cells were cultured in high-glucose DMEM supplemented
with 10% fetal bovine serum (FBS). HKB5/B5, an EBV-negative cell
clone formed by fusion of HH514-16 cells with 293T cells, was grown
in RPMI 1640medium supplementedwith 8% FBS (Chang et al., 2002).
HH-B2 cells were cultured in RPMI 1640 medium supplemented with
15% FBS (Gradoville et al., 2000). Mouse RBP-Jκ−/− (OT11) and wild
type (OT13) embryonic ﬁbroblast cell lines (Kato et al., 1997) werekindly provided by T. Honjo (Kyoto University) and were grown in
high-glucose DMEM supplemented with 10% FBS and 100 U/ml of
mouse interferon gamma. HH-B2(Tet-On-F-ORF50) cell clones har-
boring the doxycycline (Dox)-regulated ORF50 expression system
were derived from HH-B2 cells by two selection steps according to
user manual of the Tet-On Advanced Inducible Gene Expression
System (Clontech). One of the selected clones was used in the study
and was maintained in the medium with 100 μg G418 per ml and
400 μg hygromycin per ml. For induction of the exogenous ORF50
protein in the cell clone, doxycycline (Sigma) was added in 1 μg per
ml. All transfection experiments were performed in the study using
Lipofetamine 2000 (Invitrogen).Northern blot analysis
HH-B2 cells were treated with 3 mM sodium butyrate in the
presence or absence of 200 μg phosphonoacetic acid (PAA) per ml for
12, 24, 36 and 48 h. Total cellular RNAs from the treated HH-B2 cells
(1.2×107) were prepared with an RNeasy kit (QIAGEN), fractionated
on 1% formaldehyde-agarose gels, and transferred to nylon mem-
branes (Hybond-N; Amershann Pharmacia Biotec). The probe
Fig. 7. Down-regulation of YY1, Sp1 and Sp3 expression during KSHV lytic replication.
(A) HHB2 cells treated with 3 mM sodium butyrate (SB) for 24 and 48 h were analyzed
for the expression of ORF50, K8, YY1, Sp1, Sp3 and actin. (B) Expression proﬁle of the
viral and cellular proteins in HH-B2(Tet-On-F-ORF50) cells treated with doxycycline
(Dox). HH-B2(Tet-On-F-ORF50) derived from HH-B2 contains an exogenously
doxycycline-regulated ORF50 gene. After doxycycline treatment, the cells were
harvested at different time points and the protein extracts were prepared for detecting
the abundance of ORF50, K8, YY1, Sp1, Sp3 and actin.
Fig. 8. Inhibition of the ORF60p activation by over-expressing YY1. Fixed amount
(0.8 μg) of plasmid DNA, including the reporter and the indicated effectors, was
transfected into HH-B2 cells. At 24-h post-transfection, the luciferase activity of the
pE2F/E4luc (A), pORF60p(−71/−32)/E4luc (B) and pORF61p(−194/−155)/E4luc
(C) was determined. The relative activation of these three reporters by ORF50 in the
presence of the increasing amounts of YY1 was summarized in (D).
319S.-S. Wang et al. / Virology 397 (2010) 311–321corresponding to nucleotides 97527 to 97843 of KSHV genome was
synthesized and labeled with 0.1 M digoxigenin (DIG) DNA mix
(Roche) by PCR. Hybridization was performed according to the
protocol described previously (Chang et al., 2005). After removal of
excessive DIG-labeled probe, an anti-DIG antibody conjugated with
alkaline phosphatase (1:10,000; Roche) was added. The membrane
was then incubated with the enzymatic substrate CSPD (1:100;
Roche) to display the speciﬁc signals.
Rapid ampliﬁcation of 5′ cDNA ends (RACE)
The transcriptional start sites were mapped using the GeneRacer
kit (Invitrogen). Brieﬂy, HH-B2 cells were treated with 3 mM sodium
butyrate for 30 h and total RNA was prepared from the treated cells.
Two micrograms of total RNA was treated with calf intestinal
phosphatase to remove the 5′ phosphates of truncated mRNA and
non-mRNA. After decapping of full-length mRNA by tobacco acid
pyrophophatase, an RNA linker oligonucleotide was ligated to the
mRNA by T4 RNA ligase. The ﬁrst-strand cDNA was obtained by
reverse transcription using random primers. Subsequent PCR and
nested PCR ampliﬁcation were carried out using the gene speciﬁc
primers and the linker primers provided in the kit. The ORF61 speciﬁc
primers used in the initial PCR and nested PCR were 5′-CTCATTCAT-
CATGGAGGGCTGCA and 5′-CGTACTCCACTATAGCCATCTCAG, while
the ORF60 speciﬁc primers were 5′-CACGACACCGTGGATATTCTCCATG
and 5′-TAATAGTGGGCCACGTCGTGGCTGT. The ampliﬁed DNA frag-
ments were cloned and sequenced. All clones of the ORF61 gene had
the same start sitemapped at nt 100329 of KSHV genome (Russo et al.,
1996). Six out of ten clones of the ORF60 gene were initiated at nt
97843, while three clones at nt 97845.
Plasmid construction
The DNA fragments of the PAN, ORF57, ORF61 and ORF60
promoters were ampliﬁed by PCR from viral genome of HH-B2
total DNA and cloned into pGL3-Basic (Promega) digested with
HindIII (or XhoI) and NheI. The plasmids including pE4luc, pCMV-
FLAG-ORF50, pCMV-FLAG-RBPJκ and pCMV-FLAG-ORF50(1–390)were described previously (Chang and Miller, 2004; Chang et al.,
2002, 2008). The plasmid pCMV-FLAG-Sp1(300–785)was constructed
by inserting a DNA fragment that encodes aa 300 to 785 of Sp1 to
pFLAG-CMV-2 (Sigma) with EcoRI and XbaI. The double-stranded
oligonucleotides or PCR-ampliﬁed DNA fragments shown in Figs. 3B, 4
and 5B were cloned into pE4luc digested with NheI and XhoI. The
plasmid pE2F/E4luc contains two copies of the E2F binding site,
5′-AGTTTCGCGCCCTTTCTCAA, in pE4luc.
Luciferase assays
293T, HKB5/B5, HH-B2, OT11 and OT13 cells (7×105) were
transfected with a ﬁxed amount (0.8 μg) of plasmid DNA, including
the reporter and effector plasmids. The reporter assays were carried
out according to manufacturer's protocol for the luciferase reporter
assay system (Promega). Activation was calculated as luciferase
activity in the presence of activator divided by that in the presence
of control vector. The value of fold activation represents at least three
independent experimentswith duplicate samples in each transfection.
Electrophoretic mobility shift assay (EMSA)
Protein extracts for EMSAs were prepared from HKB5/B5 or HH-
B2 cells. The cells were suspended in a lysis buffer (0.42 M NaCl,
20 mM HEPES [pH 7.5], 25% glycerol, 1.5 mM MgCl2, 0.2 mM EDTA,
1 mM dithiothreitol, 1 mM phenylmethylsulfonyl ﬂuoride, 2 μg
aprotinin/ml). Lysates were centrifuged at 90,000 rpm at 4 °C for
15min in a benchtop ultracentrifuge and supernatantswere harvested
and stored at −80 °C. Annealed double-stranded oligonucleotides
were end-labeled with biotin-11-UTP using terminal deoxynucleoti-
dyl transferase (PIERCE). Binding reactions contained 10 to 15 μg of
Fig. 9. Association of the ORF50 protein with the ORF61 and ORF60 promoters in vivo. The cross-linked chromatin fromHH-B2 cells treated with sodium butyrate for 24 h (A) or from
HH-B2(Tet-On-F-ORF50) cells treated with doxycycline for 24 h (B) was prepared for chromatin immunoprecipitation. Immunoprecipitation was performed using antibodies to
ORF50, actin and RBP-Jκ. Associations between proteins and promoters were detected by PCR using primers speciﬁc for the promoter regions of PAN, ORF57, ORF61, ORF60, ORF62
and LANA as well as for the coding region of ORF65. Lanes M, molecular size marker.
320 S.-S. Wang et al. / Virology 397 (2010) 311–321protein extract in a solution containing 10mMHEPES (pH 7.5), 50mM
NaCl, 2 mM MgCl2, 2.5 μM ZnSO4, 0.5 mM EDTA, 1 mM dithiothreitol,
15% glycerol and 0.5 μg poly(dIdC) in a total volume of 20 μl. For
competition assays, unlabelled competitor DNA was added to the
initial reaction mix. The speciﬁc antibodies were used for supershift
analysis.
Western blot analysis
Cell protein extracts were mixed with 3× sodium dodecyl sulfate
(SDS) gel loading buffer and boiled for 5 min before proteins were
resolved on 8% to 10% polyacrylamide gel and transferred to PVDF
membrane (BIO-RAD). The membranes were blocked in 5% non-fat
milk and incubated with diluted primary antibodies for 2 h at room
temperature or 4 °C overnight. Anti-rabbit or anti-mouse immuno-
globulin G antibody conjugated to horseradish peroxidase was used as
the secondary antibody. The enhanced chemiluminescence system
was used for detection of antibody-antigen complexes. The rabbit
polyclonal antibody against ORF50 used in the study was generated
using bacterially produced ORF50 protein (aa 1 to 590) as an antigen.
Antibodies to K8α (sc-57889; Santa Cruz), YY1 (sc-1703, sc-7341;
Santa Cruz), Sp1 (sc-59, Santa Cruz), Sp3 (sc-644, Santa Cruz) and
actin (MAB101; Chemicon) were obtained commercially.
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed as described previously (Chang and
Miller, 2004) with minor modiﬁcation. Brieﬂy, HH-B2 cells (2×106)
were treated with 3 mM sodium butyrate and HH-B2(Tet-On-F-
ORF50) cells were treated with doxycycline. After 24-h treatment,
cells were incubated with 1% formaldehyde for 10 min at 37 °C. The
cells were harvested, washed with phosphate-buffered saline, re-
suspended and sonicated. The sonicated cell lysates were precleared
with 50 μl of protein A/G agarose slurry containing 20 μg of salmon
sperm DNA and 1 mg of bovine serum albumin per ml for 1 h at 4 °C,
and then incubated with antibodies to ORF50, RBP-Jκ (sc-28713;
Santa Cruz) or actin (sc-1616; Santa-Cruz) at 4 °C overnight with
mutation. The immune complexes were precipitated with 60 μl of
protein A/G agarose slurry containing 20 μg of salmon spermDNA and1 mg of bovine serum albumin per ml for 1 h at 4 °C. After extensive
washing steps, the precipitated DNA was extracted. Four percent of
the precipitated DNAwas used as a template in PCR. Primer sequences
used in PCR were following: 5′-GGTGACCCAACATAGTGATTCGGTAG
and 5′-AGCGGCAAGAAGGCAAGCAGCGAGC for the PANp; 5′-GGAA-
GACACTTCCTCTGCATCAACC and 5′-GTCTATCATTGCTTGTACCATGTCC
for the ORF57p; 5′-GGAACTGTGCCCAGCGTACAAACC and 5′-
AGTACCTTCGTGACCAAGGTCACC for the ORF61p; 5′-GAAATCGAT-
CAACTGAATCCATTGG and 5′-TATCTTAGGGACCTGCTGCTACATG for
the ORF60p; 5′- CATATCCACGCCGGCAATGGA and 5′-GCGAACACGC-
GATAGTCGCGTA for ORF62p; 5′-CCTCGGGAAATCTGGTCTGACAAC
and 5′-CCTTGTTTACCTGGCAGGTGAGC for the LANAp; 5′-
AAAAGTGGCCGCCCTATCGGCGT and 5′-TGGAAGATGTCCAACTT-
TAAGGT for the ORF65 coding region.
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